Single-dose Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2017
At a glance
- Drugs BMS 986141 (Primary)
- Indications Liver disorders
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 02 Feb 2017 Planned End Date changed from 1 May 2017 to 7 Jul 2017.
- 02 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 09 Dec 2016 New trial record